Prognostic_factors_in_invasive_bladder_carcinoma_in_a_prospective_trial_of_preoperative_adjuvant_chemotherapy_and_radiotherapy__Clinical_and_pathologic_factors_were_analyzed_in_40_patients_with_localized_muscle-invasive_bladder_carcinoma_treated_in_a_prospective_bladder-preserving_program_consisting_of_transurethral_tumor_resection,_neoadjuvant_chemotherapy_(methotrexate,_cisplatin,_and_vinblastine_MCV),_and_4,000_cGy_radiotherapy_with_concurrent_cisplatin._Patients_with_biopsy-proven_complete_response_after_chemotherapy_and_4,000_cGy_radiation_received_full-dose_radiotherapy_(6,480_cGy)_with_cisplatin._Cystectomy_was_recommended_to_patients_with_residual_disease._Distant_metastasis_rate_was_associated_with_tumor_stage_and_size:_0%_in_T2_patients,_39%_in_T3-4_patients_(P_=_.035),_6%_for_tumors_less_than_5_cm,_and_59%_for_tumors_greater_than_or_equal_to_5_cm_(P_=_.002)._Risk_of_bladder_tumor_recurrence_was_higher_in_patients_with_tumor-associated_carcinoma_in_situ_(CIS;_40%)_than_those_without_CIS_(6%;_P_=_.075)._Papillary_tumors_and_solid_tumors_both_had_similar_treatment_outcomes._By_multivariate_analysis,_tumor_stage_T2_(P_=_.04)_and_absence_of_CIS_(P_=_.03)_were_significant_predictors_of_complete_response;_CIS_was_predictive_of_local_bladder_recurrence_(P_=_.07);_and_tumor_size_(P_=_.03),_response_after_chemoradiotherapy_(P_=_.02),_and_vascular_invasion_(P_=_.08)_were_associated_with_distant_metastasis._Six_of_eight_local_bladder_tumor_recurrences_were_superficial_tumors._The_low_actuarial_distant_metastasis_rate_of_T2_patients_(0%_at_3_years),_the_3-year_actuarial_overall_survival_rates_for_T2_(89%)_and_T3-4_(50%)_patients,_and_the_similar_treatment_outcomes_for_papillary_versus_solid_tumors_are_encouraging_when_compared_with_published_historical_controls._These_results_provide_preliminary_evidence_(median_follow-up,_30_months)_that_the_current_chemoradiotherapy_regimen_may_have_beneficial_effects_in_the_treatment_of_muscle-invasive_bladder_carcinoma._The_true_efficacy_of_neoadjuvant_chemotherapy_remains_to_be_proven_by_ongoing_randomized_trials.